Literature DB >> 7030638

Once daily flupenthixol in the treatment of elderly depressed patients: a multi-centre trial in general practice.

J C Vallé-Jones, D J Swarbrick.   

Abstract

Ninety-five elderly depressed patients were entered into an open trial of 0.5 to 1.0 mg flupenthixol dihydrochloride, as a single daily dose in the morning. Eighty-seven patients were treated and assessed for 14 days, 6 patients failed to attend follow-up appointments and 2 patients were withdrawn from the trial because of acute physical illness. After 14-days' treatment, a decrease in the severity of the illness was recorded on the Clinical Global Impression Scale in 77% of the patients, and statistically significant improvements were noted in the 5 individually rated symptoms of lowered mood, fatigue, tendency to weep, feelings of inadequacy and irritability. The number and severity of adverse effects recorded on a check-list decreased during the treatment period. The results suggest that flupenthixol is an effective antidepressant and is well tolerated by the elderly as a single daily dose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7030638     DOI: 10.1185/03007998109112371

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

Review 1.  Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management.

Authors:  Helia Ghanean; Amanda K Ceniti; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

2.  Methyl 2-[4-(tri-fluoro-meth-yl)phenyl-sulfan-yl]benzoate.

Authors:  Thammarse S Yamuna; Jerry P Jasinski; Brian J Anderson; H S Yathirajan; Manpreet Kaur
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-10-19

3.  Flupentixol tartrate.

Authors:  Thammarse S Yamuna; Manpreet Kaur; Brian J Anderson; Jerry P Jasinski; H S Yathirajan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.